MSCI's August 2026 quarterly index review brought a broad reshuffle to Chinese equities, with 33 stocks added to the MSCI China Index and 32 removed, all effective after the market close on Aug. 31. Zhipu, listed as Z.AI Co H, was the largest new constituent in the MSCI Emerging Markets Index by full company market capitalization, making it one of the most closely watched additions in the review. Because the MSCI China Index sits within the MSCI Emerging Markets Index and the broader MSCI ACWI framework, newly added names are set to enter MSCI's Global Standard Index system and typically attract buying from passive funds tracking those benchmarks, while deleted stocks can face selling pressure around the rebalance date. The new China additions were concentrated in semiconductors, pharmaceuticals, new materials and precision manufacturing. Beyond Zhipu, additions included Dingtai High-Tech, Asymchem Laboratories, Huafeng Test & Control, YanDong Microelectronic, International Composite Materials, Fenghua Advanced Technology, Jiangsu Yoke Technology, Kingsemi, Leader Harmonious Drive Systems, Nanya New Material Technology, CSSC Specialty Gases, Sinocera Materials, Shenzhen Kaifa Technology and Wuhan Jingce Electronic Group. The MSCI China A Onshore Index was adjusted in parallel, with 31 additions and 25 deletions. On the removal side, MSCI China deleted 32 stocks including China Vanke A, Zhifei Biological, Changchun High-Tech, Dajin Heavy Industry, GCL Technology, Hesai-W, Kingdee International, Mango Excellent Media, Pony.ai-W and Yonghui Superstores. Globally, MSCI said the ACWI added 55 securities and removed 92, while the MSCI Global Small Cap Index added 203 and removed 261, and the MSCI Frontier Markets Index added 6 and removed 5. In developed markets, the top three new constituents in the MSCI World Index by full company market capitalization were SanDisk, Carpenter Technology and ATI, all from the United States. MSCI also said index adjustments for Bangladesh-related securities remain suspended and are due to resume at the November 2026 review.